Tag
The DIABIL-2 trial evaluated low-dose IL-2 therapy for preserving β-cell function in new-onset type 1 diabetes. Despite marked Treg expansion and good safety, IL-2 did not significantly preserve insulin secretion compared to placebo.
The MIROCALS trial evaluated low-dose IL-2 combined with riluzole in ALS, showing safety and immunomodulatory effects, with adjusted analyses suggesting survival benefit in patients with low CSF-pNFH levels, underscoring the role of biomark
A single-center perspective-controlled trial found subcutaneous low-dose IL-2 plus corticosteroids achieved faster disease control in moderate-to-severe bullous pemphigoid and reduced total steroid exposure without serious infections, suppo
A phase 2a randomized trial found low‑dose IL‑2 given every 4 weeks was safe, expanded regulatory T cells, altered peripheral inflammatory mediators, increased CSF Aβ42, stabilized NfL, and trended toward slower cognitive decline in mild–mo
Low-dose IL-2 immunotherapy demonstrates broad, disease-modifying effects by selectively expanding regulatory T cells (Tregs), offering a promising strategy across diverse diseases including autoimmunity, neurodegeneration, metabolic dysfun
